Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab-Reference-Cited by-同舟云学术

Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

Published:2011-12-27 Issue:17 Volume:118 Page:4173-4183
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Akyurek Nalan,Uner Aysegul,Benekli Mustafa,Barista Ibrahim

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27396/fullpdf

Reference44 articles.

1. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005

2. The revised International Prognostic Index (RIPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with RCHOP;Sehn;Blood,2007

3. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era;Ziepert;J Clin Oncol,2010

4. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of New Diffuse Large B Cell Lymphoma Mouse Models;Cancers;2024-08-29

2. Advances in biology, diagnosis and treatment of DLBCL;Annals of Hematology;2024-07-17

3. Turning the tide in aggressive lymphoma: liquid biopsy for risk-adapted treatment strategies;Trends in Molecular Medicine;2024-07

4. Artificial intelligence-based prognostic model accurately predicts the survival of patients with diffuse large B-cell lymphomas: analysis of a large cohort in China;BMC Cancer;2024-05-22

5. Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma;Heliyon;2024-01